iMMagine-1 Trial

[Slide 1] 4825 Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 38.1-Month Median Follow-up Michael R. Bishop, MD1, Jacalyn Rosenblatt, MD2, Binod Dhakal, MD, MS³, Noopur Raje, MD4, Daniella Cook, BS⁵, Mahmoud Gaballa, MD6, Estelle Emmanuel-Alejandro, BA7, Danielle Nissen, BS8, Kamalika Banerjee, MA9, Rebecca J. Chan, MD, PhD9, Ana Kostic, MD Christopher R. Heery, MD9, Tim Welliver, MD. PhD9, David Avigan, MD2, Andrzej J. Jakubowiak, MD, PhD10, and Matthew Frigault, MD. MS7 1. David and Etta Jones Center for Cellular Therapy. University of Chicago, Chicago L USA 2. Beth israel Medical Center, Harvard Medical School Boston MA USA 3. Division of Hematology and Oncology Department of Medical College Milwauke, Wt, USA: 4. Harvard Medical School Boston, MA USA 5. chusetts General Hospital Cancer Center Boston MA, USA 6. The University of Texas MD Anderson Cancer Center Houston TX, USA 7. Massechusetts General Hospital Boston MA USA 8. Medical Coffege of Wisconsin, Milasure W. USA 9. Arceilx, 2% Redwood City CA USA 10. Section of Onoslogy Department of Medicine, University of Chicago, Chicago L USA Introduction Results RRMM is characterized by progressively worse outcomes with each line of Figure 3: Patient Disposition Figure 5: Median PFS for All Patients is 30.2 Months (95% CI: 16.6-NE] Safety therapy1, and novel therapies are needed to provide durable responses in later- Enrolled eukapheresed Median PFS for CR/sCR Patients is 34.3 Months (95% CI: 24.2-NE] delayed or non ICANS neurotoxicities have been observed at median follow up of 38. months line patients. - Median Follow-up of 18. Months Range 25-54) including no incidence of Parkinsonism, no cranial nerve palsies, and no syndrome While BCMA CAR T-cell therapies have demonstrated compelling clinical activity One Successful Manufacture Anito-cel patient had Grade event post study treatment cardiac arrest due on study trag overdose) in patients with RRMM, outcomes continue to be limited particularly in patients - 100 All secondary primary malignancies (SPMs) were required to be reported irrespective of relatedness or timing Discontinued + Censored with high-risk disease characteristics - No SPMs of cell origin occurred Lymphodeptetion Hematologic SPMs myelodysplastic syndrome MDS were reported in patients as unrelated AEs by the Anitocabtagene autoleucel (anito-cel previously CART-ddBCMA) is an **39 investigator, and occurred the setting of disease progression patients heavily pre- treated with agents Total Desed Hypoxia/Heart allure - 80 known be associated with MDS autologous D Domain BCMA-directed chimeric antigen receptor (CAR) T-cell therapy being studied in patients with RRMM. **30 Table Associated Alls CRS and ICANS per ASTCT Criteria (N=38) CAR The BCMA-binding Domain is small, synthetic 8 kDa protein comprised of AE's DLI 100 cells DL2: T cells Total DL1, 100 10" CAR+ cells DLZ 10" CAR+ cells Safety Efficacy e=32 60 (N=38) 73 amino acids that fold into stable triple alpha helix bundle resulting - evaluable dosed in several key attributes described in Figure 115, Dose Escalation - patients PFS (%) CRS Grt G/2 Gr3 Gr4 Grt Gr2 Gr3 Gr4 Any Or Dose Escalation - --38 Max grade, (%) Expansion Cohort, **25 15(47%) 0.(0%) 3 (50%) 2(33%) (17%) 00(95%) This report presents efficacy and safety results with a median follow-up of 38. onset I 2 days months from the human Phase study of anito-cel in patients with 4L+ dose at 115 million cells (range, 112 million cells) 40 Arabon' max) 9 days) 9 days) RRMM Table 1: Patient and Disease Characteristics ICANS Grt Gr2 Gr3 Gr4 Grt Orz Gr3 Gre Any Figure 1: D-Domain Attributes Non-Antibody-Derived Synthetic Protein Max grade, (%) 3 (9%) (6%) 13%) 0 (0%) 0.00%) 0(0%) 1 (17%) 0 (0%) (10%) DL Total Small Domain construct Characteristics CAR+ cells CAR+ cells 20 onset jmin max) days 6 days) 7 days facilities high transduction (6*32) (w*34) I max) 17 days efficiency CAR positivity and CAR Age, median max) 56 76) density surface" All Subjects With CR/sCR Toxicity 19 (30%) 1(17%) 20 (53%) 0 Tockpumab (84%) 5(53%) Rapid Demain folding tack of Gonder I I 20(63%) (33%) 22(58%) Stability disulfide bonds, and a Place 0 6 12 18 24 30 36 42 48 54 60 emables - I -Domain CAR - White 20(00%) 4,67%) 22(64%) Time from Infusion (Months) black African American 3 (P%) 1,000 4(17%) Table Grade AEs per CTCAE after infusion (N+38) - - Asian (7%) 0(0%) 10%) n(%) n(%) structure Domale CARS have Other (7%) 100 10% - 14 33,(86.8%) Hypertension (7.9%) Structure - - signating - ECOG PS* Bivalent VHh D-Domain potentially more multiple Anemia 21.(55.3%) Preumonia 3 (7.9%) - - Res I (-25 kDa) kDa) 6(100%) 26 (68%) Estimated PFS Rate Patients (N-28) CRACR Patients (n+30) 17 AST* increased 2(6.3%) Prior Lines Therapy median - - (3.7) (3.18) 5-month 2 (%) Cardies arrest 2 (5.3%) (3-14) Methods 12 8 (21.1%) Celluits 2 (5.3%) refractory 6(100%) 30(100%) 5 (83%) 18 Febrie Pente refractory neutropenia 6(15.0%) Hypokalemia 2(5.3%) First-in-human Phase 1, multi-center, dose escalation trial in 4L+ RRMM Prior ASCT 25(78%) 4,67%) 29(70%) È Hyponetremes 2 (5.3%) Eligibility Time since diagnosis median 65years PFS Hypophosphatomisma 2 (6.3%) At least 3 prior lines of therapy including a PL IMD. and anti-CD38 antibody; (mm max) I Pain extremity 2 (5.3%) bridging therapy 20-(63%) 6(100%) I or triple-refractory disease following treatment with a PI, IMID, and anti-CD38 Figure 6: Median os for All Patients is Not Reached I I Sepsis* 2(5.3%) antibody as part of the same or different regimens - no - I - Median Follow of Months (Range: 25-54) Urinary tract infection 2(5.3%) and - - Measurable disease per at least of the criteria: serum M-protein 0 g/dL. unine M protein >200 mg/24 hours: involved serum free light chain >100 mg/L Figure 4: Best Overall Response Rate and MRD Negativity Conclusions 100 + Censored with abnormal K/A ratio; >1 extramedullary lesion on imaging, including at 100% ORR Anito-cel utilizes novel, synthetic, compact and stable Domain binder that facilitates high least lesion that is 21 cm and able to be followed by imaging assessments; 38 total patients (79%) achieved CR&CR or BMPCs >30% 12% transduction efficiency, CAR positivity, and CAR density on the T-cell surface. . 89% evaluable* patients wore MRD negative . 80 ECOG PS of or and adequate organ function minimum of sensitivity With median follow-up of 38. months, anito-cel achieved rapid, high response rates with long- term durable remissions in a refractory. heavily pre- treated population of whom 68% had high- Primary Endpoints: Incidence of TEAEs DLTs: establish the RP2D . word origoing 38 (39%): patients risk features: Select Secondary Endpoints BOR and ORR by IMWG Consensus Criteria11 median follow-up of months (%) EVUPK 60 CR achieved in 79% of patients Select Exploratory Endpoints: MRD negativity, DOR, PFS. os 2CR 79% 92% 79% os Median PFS of 30.2 months in an patients and 34.3 months in patients with 2CR Toxicity grading was performed per NCI CTCAE v 5.0. except for CRS and Median os not reached CANS which were graded per ASTCT consensus criteria time best Data cut-off: October 3. 2024 response 40 Similar efficacy and durable remissions were observed across high-risk subgroups CRNCR The anito-cel safety profile is predictable and manageable Figure 2: Phase Dose Escalation Study Design All Median time MRD regalivity of 10(09-56) No delayed or non-ICANS neurotoxicities including no Parkinsonism no cranial nerve Median duration response (95% 20 palsies, and no Guillain Barre syndrome were observed across the Phase and Phase 2 Chemotherapy (MMagine- 1)" dinical trials. Anito-cel efficacy & safety compares favorably with available treatments for RRMM, including for Apheresis Day 4. Table 2: Kaplan Estimated PFS Rates in All Patients & High-Risk Subgroups 0 RRMM bearing high-risk features Anito-cel is being developed with Kite's global bell therapy leadership infusion 0 6 12 18 24 30 36 42 48 54 60 CAR-T Day 0 24 Magine-1 NCT05396885) in the photal Phase trial evaluating anito-cel in patients with RRMM and X prior Patients n Time from Infusion (Months) months LOT including inhibitor, an IMD, and an anti- CD38 entibody Screening, (524) Dose AS B Escalation * " 13 1 . Consent, cells 12-month $ 75.9 72.2 Magine-3 is global, Phase trial comparing anito-cet to standard of care therapy patients Enrollment Optional I with RRMM after 1-3 prior LOT, including an anti- CD38 antibody and an IMID 1 500 CARY I Safety Follow- Patients Estimated Rate Therapy 24-manth PFS % %(96%C) Acknowledgments Expansion Cohort enrolled DL1 years post- S-nonth 05 are (92.8. The patients and their families cell infusion 10-manth 50.3 60.2 06 The staff caregivers, research coordinators and investigators at each participating institution 6 (330.65.3) (295,727) American - Therapy - FOR 06 zux - IN Ferment - Common I - DOR, - ECOD CANS MO estimated median reached 8 - - I = Card I I black - I : - , I I I NO. National - ! - 1 - I 20% - - Pear 3 15.1 I 204 AIR I the Presented at the American Society of Hematology 2024 Annual Meeting --- [Slide 2] iMMagine-1: Overall Response Rate and MRD Negativity Efficacy Evaluable Patients (N=86) ORR=97% 15% At a median follow-up of 9.5 months, ORR was 97% and sCR/CR rate was 62% 20% 93.1% (n=54/58) of evaluable patients were MRD negative at minimum of 10-⁵ sensitivity ≥VGPR 81% Evaluable 62% sCR/CR Patients Months (min - max) 62% Median time to first response 83 1.0 (0.9 7.3) Median time to MRD negativity of ≤10-⁵ 54 1.0 (0.9 6.4) Efficacy Evaluable Patients (N=86) Best Response: sCR/CR VGPR PR --- [Slide 3] PFS Rate (%) os Rate (%) (95% CI) (95% CI) 93.3% 96.5% 6-Month (84.4%, 97.2%) (89.6%, 98.9%) 78.5% 96.5% 12-Month (63.5%, 87.9%) (89.6%, 98.9%)

[Slide 1] Abstract M X in PHASE 2 REGISTRATIONAL STUDY OF ANITOCABTAGENE AUTOLEUCEL FOR This abstract is embargoed until Thursday, June 12, 2025, 08:00 CEST. RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED Presentation during EHA2025: All Oral presentations will be presented between Thursday, June 12 and Sunday, June 15, 2025 and will RESULTS FROM IMMAGINE-1 be accessible for on-demand viewing from June 18 to August 15, 2025 on the Congress platform. Gurbakhash Kaur Author(s): Gurbakhash Kaur, Ciara L. Freeman, Binod Dhakal, Richard T. Maziarz, Natalie Callander, Adam S. Sperling. Carolina D. Schinke, Andrzej J. Jakubowiak, Noa Biran, Abstract: S201 Douglas W. Sborov, Cindy Varga, Larry D. Anderson, Jr., Abhinav Deol, Abraham S. Kanate, Mehmet H. Kocoglu, Title: PHASE 2 REGISTRATIONAL STUDY OF ANITOCABTAGENE AUTOLEUCEL FOR RELAPSED AND/OR REFRACTORY Melhem M. Solh, Kamalika Banerjee, Krishna Rana, MULTIPLE MYELOMA (RRMM): UPDATED RESULTS FROM IMMAGINE-1 Ana Kostic, Enrigue Granados, Carolyn C. Jackson, Christopher R. Heery, Tim Welliver, Krina K. Patel, Type: Oral Presentation Matthew J. Frigault (Abstract release date: 05/14/25) EHA Library. Kaur G. 06/14/2025; Session title: Treatment of relapsed and/or refractory multiple myeloma (RRMM) 4159278; S201

[Slide 1] LL&M winter symposium from + Lymphoma Leukemia k Myeloma Congress BCMA CAR-T in 2025 Other risks Relative risk of death from MAS/IEC-HS ICAHT myeloma 1 LOT Infections Early (2-3 LOT) Delayed neurotoxicity VS Refractory VS exposed Cranial nerve palsy Functional high-risk GBS Parkinsonian-like Access to CAR-T syndrome Any BCMA CAR-T is better Behavioral changes than NO CAR-T Do all patients need CAR-T in 2ⁿᵈ relapse? - No But CAR-T should be discussed in all patients - Yes IEC-HS = immune effector cell associated hemophagocytic lymphohistiocytosis-like syndrome; MAS = macrophage activation-like syndrome; ICAHT = immune effector cell-associated hematotoxicity; GBS = Guillain-Barré syndrome. llmwintersymposium.com --- [Slide 2] LL&M winter symposium from * Lymphoma Leukemia & Myeloma Congress Anito-Cel: A Highly Active BCMA CAR-T Anitocabtagene autoleucel (anito-cel) has a novel ddBCMA CAR-T design 100% ORR 100 + Censored 8% High-expression = Cell dose 13% 80 mPFS: 30.2 months Novel D-domain 60 Tonic stimulation PFS (%) ddBMCA stability Anito-cel Phase - 2VGP 40 2CR 79% 92% 79% 20 All Subjects — With CR/sCR 0 All Patients 0 6 12 18 24 30 36 42 48 54 60 4188 (N=38) Time from Infusion (Months) 4188 4188 All Subjects 38 34 28 24 19 12 6 3 2 1 0 sCR/CR VGPR #PR With CR/sCR 30 28 26 23 19 12 6 3 2 1 0 CD3C CD3C CD3C scFv Bivalent camelid VHh D-Domain (~25 kDa) (~25 kDa) (~8 kDa) No cases of delayed neurotoxicity - 38 patients - mFU: 34 months Bishop M, et al. Presented at: ASH; Dec 9, 2024; San Diego, CA. 4825. Ilmwintersymposium.com --- [Slide 3] LL&M winter symposium - + Complete Compress Predictors of Achieving MRD Neg - - NOw - 13 1.00 sBCMA at pre-infusion Cmax Measuring CAR-T in the Clinical Setting B OF I I I 0.75 1.0 P-0.516 P-0.019 I I 3 5- 0.00 0.5 0.29 0.0 P<0001 0.00 0 1 0 10 30 30 40 so «BCMA preinfusion, logo pot 10°cella/L 4. 2 Steel 7 1- J 1 10 3 C Day part CAB-T Months 2 0- CD4+ Tasive at apheresis* CD4+ TEM at apheresis IFN-Y at pre-infusion n-116 n=17 1 9=117 n=17 Regative Positive Negative Positive 50 P-0.013 00- P-0.000606 P-0.02 60- Blood naive CLCD4 CARJ, 40- BLOOD EM EMPLCD4 CAR-1, Lop. Serum into interferon gamma, npt 2 40 How to avoid "unfit" T-cells? Earlier CAR-T 20- X 20- 1. Treatments (eg alkylators?) T-cell deterioration 0- - - n-109 n-16 0. n=109 n-16 n=199 n-16 Rescue T-cells (CelMod?) Regative Positive Regative Positive Regative Positive Popat R, et al. Presented at: ASH; Dec 9, 2024; San Diego, CA. 1032. Mejia Saldarriaga, et al. Blood Adv. 2024;8(15): 3859-3869. Imwintersymposiun.com --- [Slide 4] LL&M winter symposium from * Lymphoma Leukemia & Myeloma Congress IMMagine-1 Anito-Cel - Efficacy ORR=97% Efficacy population: 86 patients 15% Median follow-up: 9.5 months Highly active: 20% ORR 97% Evaluable Patients Months (min max) sCR/CR 62% Median time to first response 83 1.0 (0.9 7.3) Fast acting: Median time to MRD negativity of ≤10⁻⁵ 54 1.0 (0.9 6.4) ≥VGPR Median time to 81% PFS Rate (%) 62% sCR/CR response 1 os Rate (%) (95% CI) (95% CI) 62% month 93.3% 96.5% 6-Month (84.4%, 97.2%) (89.6%, 98.9%) Deep responses: 78.5% 96.5% 12-Month Efficacy Evaluable Patients 93.1% MRD neg (63.5%, 87.9%) (89.6%, 98.9%) (N=86) 54/58 patients Best Response: sCR/CR VGPR PR Freeman C, et al. Presented at: ASH; Dec 9, 2024; San Diego, CA. 1031. Ilmwintersymposium.com

[Slide 1] iMMagine-1: Immune-effector Cell-associated Neurotoxicity Syndrome (ICANS) ICANS Maximum ICANS Grade (N=117) N=117 Per ASTCT criteria 108 Median onset (min-max) 7 days (2-10ᵃ days) (92%) Median duration (min-maxᵇ) 4 days (1-12b days) Supportive Measures Tocilizumab 3% (3/117) 4 4 1 (3%) (3%) 0 0 (1%) Dexamethasone 5% (6/117) (0%) (0%) No ICANS Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Anakinra 1% (1/117) Siltuximab 1% (1/117) 8% (9/117) of patients had ICANS of any grade; all cases resolved No delayed or non-ICANS neurotoxicities were observed, including no With the exception of n=1 Grade 1 ICANS (confusion) on day 31 post infusion that rapidly resolved incidence of Parkinsonism, no cranial nerve palsies, and no Guillain- b With the exception of n=1 max Grade 2 ICANS with 29-day duration to resolution Barré syndrome (n=117; median follow-up of 12.6 months, range: 5-29 months) Similarly, no delayed or non-ICANS neurotoxicities have been observed in the Phase 1 study (n=38; median follow-up of 38.1 months, range: 25-56 months) 1 Bishop MR, et al Blood (2024) 144 (Supplement 1) 4825 as presented in poster #4825 at ASH 2024 ASTCT American Society for Transplantation and Cellular Therapy --- [Slide 2] iMMagine-1: Cytokine Release Syndrome Maximum CRS Grade (N=117) Cytokine Release Syndrome (CRS) N=117 Per ASTCT criteria 82 Median onset (min-max) 4 days (1-17 days) (70%) Median duration (min-max) 2 days (1-9 days) Supportive Measures Tocilizumab 77% (90/117) 17 17 (15%) (15%) Dexamethasone 73% (85/117) 0 0 1 Anakinra 11% (13/117) (0%) (0%) (1%) Siltuximab 3% (4/117) No CRS Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Vasopressor used 1% (1/117) Intubation/mechanical ventilation 1% (1/117) 85% (99/117) of patients had CRS Grade 1 or less, including 15% (17/117) with no CRS; the median onset was 4 days CRS management per protocol was in line with standard medical practice with no prophylactic administration of tocilizumab or dexamethasone % of patients with either no CRS or CRS that resolved by: For CRS onset in the first 48 hours, tocilizumab and dexamethasone were <7 days of anito-cel infusion: 80% (94/117) protocol recommended <10 days of anito-cel infusion: 97% (114/117) For CRS onset after the first 48 hours, if tocilizumab was administered at investigator discretion, dexamethasone was also recommended 71% (83/117) of patients either received no dexamethasone or a single 10 Grade 5 CRS occurred in a 76-year-old patient who had rapidly progressive mg dose of dexamethasone for CRS management disease between screening and baseline and did not respond to bridging therapy ASTCT Amencan Society for Transplantation and Cellular Therapy --- [Slide 3] iMMagine-1: PFS and OS Rates Estimated by Kaplan-Meier N=117 PFS Rate (%) os Rate (%) (95% CI) (95% CI) 91.9% 96.6% 6-Month (85.0%, 95.7%) (91.1%, 98.7%) 79.3% 95.2% 12-Month (68.6%, 86.7%) (88.7%, 98.0%) Median follow-up of 12 6 months (range 5 to 29 months) PFS, progression free survival; OS, overall survival --- [Slide 4] iMMagine-1: Treatment-Emergent Adverse Events (Non-CRS/Non-ICANS): Any Grade AEs ≥20% Grade 3/4 AEs after cell infusion after cell infusion (N=117) (N=117) The most common Grade 3 and higher treatment- emergent AEs (TEAEs) were cytopenias Hematologic Neutropenia 79 (68%) 77 (66%) Anemia 32 (27%) 28 (24%) No cases of immune effector cell-associated Thrombocytopenia 28 (24%) 28 (24%) enterocolitis have been reported Non-hematologic No replication competent lentivirus detected Fatigue 42 (36%) 3 (3%) Hypogammaglobulinemia 40 (34%) 1 (1%) Headache 35 (30%) 2 (2%) No secondary primary malignancies of T-cell origin or Hypophosphatemia 34 (29%) 2 (2%) hematologic malignancies were reported Nausea 32 (27%) 1 (1%) Diarrhea 32 (27%) 1 (1%) Three deaths occurred due to TEAEs (related and Hypertension 23 (20%) 12 (10%) unrelated to anito-cel) Hypokalemia 23 (20%) 2 (2%) - Retroperitoneal hemorrhage* secondary to biopsy complication Infections 61 (52%) 11 (9%) - Cytokine Release Syndrome Upper respiratory tract infection 15 (13%) 2 (2%) Urinary tract infection 8 (7%) 2 (2%) - Fungal infection COVID-19 7 (6%) 1 (1%) "At baseline prior to infusion the patient developed plasma cell leukemia, which was an exclusion critena. Evidence of Grade 4 hemophagocytic lymphohistiocytosis at time of death (only case to date) TEAE IS defined as, 1) any AE with onset date on or after the first anito-cel infusion until 90 days after the first anito-cel infusion regardless of causality assessment or until start of subsequent ti-myeloma therapy whichever is earlier or 2) any AE occurring at any time assessed by the investigator as related to anito- cel

[Slide 1] Kite A ARCELLX A GILEAD Company